Preventing Recurrence of Primary Sclerosing Cholangitis After Liver Transplant (PROP-LT): a Phase 1, Open-label, Controlled Study of Oral Vancomycin
Yael R. Nobel
Summary
Primary Objective: * To evaluate safety of a 4-week course of oral vancomycin (250 mg 3 times daily \[TID\]) in liver transplant recipients who were transplanted for Primary Sclerosing Cholangitis (PSC). Secondary Objectives: * To determine tolerability and adherence to a 4-week course of oral vancomycin (250 mg TID) in liver transplant recipients who were transplanted for PSC. * To assess vancomycin resistant enterococcus (VRE) colonization status over time. * To assess the impact of oral vancomycin on stool microbiome composition, diversity, and function. * To assess impact of oral vancomycin on microbial metabolite concentrations in blood and stool. * To assess impact of oral vancomycin on liver-related biochemical markers.
Description
Primary sclerosing cholangitis (PSC) is a chronic, progressive cholestatic liver disease characterized by inflammation and fibrosis of the intrahepatic and extrahepatic bile ducts, often associated with inflammatory bowel disease (IBD). A subset of patients ultimately require liver transplantation, yet rPSC occurs in approximately 25-30% of transplant recipients and can lead to graft failure and re-transplantation. There is increasing evidence that the gut microbiome plays a role in PSC and rPSC pathogenesis. Altered microbiota composition has been identified in patients with PSC. This associ…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Age ≥ 18 years * Ability to provide written, informed consent. * History of orthotopic liver transplantation within 1 to 10 years prior to enrollment (i.e. study drug initiation) * Diagnosis of PSC as the underlying liver disease leading to liver transplantation, based on compatible imaging findings (magnetic resonance cholangiopancreatography \[MRCP\], endoscopic retrograde cholangiopancreatography \[ERCP\], percutaneous transhepatic cholangiogram \[PTC\]), liver histology, and/or clinician judgment * Subjects with or without IBD may be enrolled. IBD diagnosis with a mi…
Interventions
- DrugOral Vancomycin
Vancomycin 250 mg orally three times per day (TID, 750 mg/day), with doses spaced approximately 8 hours apart (e.g., morning, midday, evening), for a total duration of 4 weeks. Missed doses will not be made up; participants will be instructed to resume the next scheduled dose. Vancomycin is a glycopeptide antibiotic supplied as oral capsules 250 mg. It acts by inhibiting bacterial cell wall synthesis. Oral vancomycin is minimally absorbed in patients with intact gut mucosa, resulting in high intraluminal concentrations.
Location
- Columbia UniversityNew York, New York